Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Gain Therapeutics Presents New Preclinical Data of Drug Candidate

Success story interview with Dr. Manolo Bellotto, Gain

Gain Therapeutics: Focused on developing new medicines for protein

Jeffrey Riley on LinkedIn: Very proud of the progress that Gain

Matthias Alder - CEO at Gain Therapeutics

Bethesda's Gain Therapeutics Announces Pricing of IPO of Common

Buy Gain Therapeutics Stock - GANX Stock Price Today & News

Roshan Ahmed on LinkedIn: Huge milestone for the Gain Therapeutics

Gain Therapeutics' Small Molecule Approach for CNS Diseases

Swiss biotech restores motor function in mice with Parkinson's disease

What Kind Of Investors Own Most Of Gain Therapeutics, Inc. (NASDAQ